Fellowship, Postdoctoral Fellow, Center for Cancer Research, National Cancer Institute, NIH (2020)
Graduate Research Assistant, School of Medicine, Indiana University (2017)
PhD, Cancer Pathology, University at Buffalo, Roswell Park Cancer Institute Division (2017)
BS, College of Liberal Arts & Sciences, State University of New York at Fredonia (2009)
Employment:
Assistant Professor, Department of Medicine, Division of Hematology/Oncology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo (2022-present)
Graduate Faculty Member, Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo (2022-present)
Adjunct Research Assistant Professor, Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo (2021-present)
Research Assistant Professor, Department of Medicine, Division of Hematology/Oncology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo (2021–2022)
Research Technician, Health Research Inc. Roswell Park Cancer Institute (2010–2012)
Awards and Honors:
Clinical and Translational Science Institute Pilot Award (2022)
Invited panel speaker, Prostate Cancer Foundation Women in Science Forum: Celebration of Achievements of Women in Prostate Cancer Oncology and Research, Prostate Cancer Foundation (PCF) 22nd Annual Retreat (2021)
Troup Award (2021)
Clinical Translational Science Institution (CSTI) K Scholar (2021)
Prostate Cancer Foundation Young Investigator Award (2019)
Congressionally Directed Medical Research Programs, PCRP Early Investigator Research Award (2019)
Scholar-in-Training Travel Award (2016)
Cancer research day Indiana University, 2nd prize-Poster presentation award (2015)
1st prize-Award for outstanding postdoctoral fellow and graduate student poster presentation (2014)
Research Expertise:
Development and characterization of patient derived xenografts models for preclinical investigation.
Evaluating the efficacy of novel pipeline agents/compounds in 3D organoid cultures and animal models.
Functional transcriptomics and epigenetic in prostate and kidney cancers
Research Centers:
Center for Computational Research (CCR)
Center of Excellence in Bioinformatics and Life Sciences
Clinical and Translational Research Center (CTRC)
Grants and Sponsored Research:
June 2021–June 2023 Targeting drivers of non-canonical AR cistrome associated with therapeutic resistance in advanced prostate cancer Kaleida Health Foundation Role: Principal Investigator
October 2019–October 2022 Investigating Alterations in AR regulome following response to Kinase Inhibitors Prostate Cancer Foundation Role: Principal Investigator
September 2019–October 2021 Dynamics of Epigenetic Mechanisms in the Akt Signaling Pathway and Its Influences on Drug Response in Advanced Prostate Cancer DOD-CDMRP-PCRP Role: Principal Investigator
March 2022 Hijacking Therapeutic Resistance in High-risk Localized and Advanced Prostate Cancer University at Buffalo Clinical and Translational Science Institute (CTSI) via the NIH CTSA UL1 Role: Principal Investigator
Orillion A, Damayanti NP, Shen L, Adelaiye-Ogala R, Affronti H, Elbanna M, Chintala S, Ciesielski M, Fontana L, Kao C, Elzey BD, Ratliff TL, Nelson DE, Smiraglia D, Abrams SI, Pili R. (2018) Dietary Protein Restriction Reprograms Tumor-Associated Macrophages and Enhances Immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research (Dec), 24(24): 6383-6395. doi:10.1158/1078-0432.CCR-18-0980
Damayanti NP, Budka JA, Khella HWZ, Ferris MW, Ku SY, Kauffman E, Wood AC, Ahmed K, Chintala VN, Adelaiye-Ogala R, Elbanna M, Orillion A, Chintala S, Kao C, Linehan WM, Yousef GM, Hollenhorst PC, Pili R. (2018) Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research (Dec), 24(23): 5977-5989. doi:10.1158/1078-0432.CCR-18-0269
Adelaiye-Ogala R, Budka J, Damayanti NP, Arrington J, Ferris M, Hsu CC, Chintala S, Orillion A, Miles KM, Shen L, Elbanna M, Ciamporcero E, Arisa S, Pettazzoni P, Draetta GF, Seshadri M, Hancock B, Radovich M, Kota J, Buck M, Keilhack H, McCarthy BP, Persohn SA, Territo PR, Zang Y, Irudayaraj J, Tao WA, Hollenhorst P, Pili R. (2017) EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming. Cancer research (Dec), 77(23): 6651-6666. doi:10.1158/0008-5472.CAN-17-0899
American Association for the Advancement of Science (2014–2019)
American Society for Clinical Oncology (ASCO) (2012–present)
American Association for Cancer Research (AACR) (2011–present)
Presentations:
"Effective Communication to Diverse Audiences" CTSI Scientific Communications Workshop Series, UB Clinical and Translational Science Institute- Workforce Development core (2022)
"Alterations in AR regulome associated with systemic therapies for advanced prostate cancers" Cancer Research Consortium Seminar Series, University at Buffalo-Cancer Research Consortium (2021)
"Epigenetic alterations associated with resistance to therapy: Focus in advanced renal cell carcinoma" Seminar, Department of Medicine, Imperial College, (2018)